Skip to Content

SODIUM CHLORIDE 5% INTRAVENOUS INFUSION

Active substance(s): SODIUM CHLORIDE / SODIUM CHLORIDE

View full screen / Print PDF » Download PDF ⇩
Transcript
SUMMARY OF PRODUCT CHARACTERISTICS
1

NAME OF THE MEDICINAL PRODUCT
Sodium Chloride 5% Intravenous Infusion

2

QUALITATIVE AND QUANTITATIVE COMPOSITION
Sodium Chloride 5% Intravenous Infusion has the following composition:

3

Name

%w/v

Sodium Chloride

5.0

PHARMACEUTICAL FORM
Intravenous fluid

4

CLINICAL PARTICULARS

4.1

Therapeutic indications
Sodium Chloride 5% Intravenous Infusion is used in the treatment of acute sodium
deficiency and water intoxication.

4.2

Posology and method of administration
Adults and Children
The rate of administration and volume infused will depend upon the requirements of
the individual patient and the judgement of the physician
Elderly
Care should be taken to avoid circulatory overload, particularly in patients with
cardiac and renal insufficiency.
For intravenous infusion

4.3

Contraindications
Patients with sodium overload. This may occur with myocardial and renal damage,
but it should also be appreciated that in the first five or six days after surgery or
severe trauma there may be an inability to excrete unwanted sodium.

4.4

Special warnings and precautions for use
Sodium Chloride 5% Intravenous Infusion is not suitable for protracted use unless
there is heavy continued loss of electrolytes; even then it should be used with care.
Saline solutions should not be administered
particularly in infants and the elderly.

rapidly or for prolonged periods

A too rapid injection of hypertonic saline may cause sudden cardiac arrest or
circulatory overloading.
In potassium deficient patients, administration of saline will increase potassium loss,
so that if it is given, potassium supplements should also be given.
The solution is hypertonic.
Restrict intake in impaired renal function, cardiac failure, hypertension, peripheral
and pulmonary oedema, toxaemia of pregnancy. This guidance is particularly
relevant for isotonic and hypertonic forms.
The label states: Do not use unless the solution is clear and free from particles.

4.5

Interaction with other medicinal products and other forms of interaction
No clinically significant interactions.

4.6

Fertility, pregnancy and lactation
The safety of the solution during pregnancy and lactation has not been assessed, but
its use during these periods is not considered to constitute a hazard.

4.7

Effects on ability to drive and use machines
Not applicable.

4.8

Undesirable effects
Thrombosis of the chosen vein is always a possibility with intravenous infusion If
infusion is protracted then another vein should be selected after 12 - 24 hours.

4.9

Overdose
Overdosage may lead to fluid overload, electrolyte imbalance, in particular
hypematraemia.

Treatment should consist of discontinuing the infusion and, if necessary
administering a diuretic.

5

PHARMACOLOGICAL PROPERTIES

5.1

Pharmacodynamic properties
Sodium chloride provides a source of sodium and chloride ions to maintain the
osmotic tension of the extracellular fluid and tissues.

5.2

Pharmacokinetic properties
Not applicable.

5.3

Preclinical safety data
None stated.

6

PHARMACEUTICAL PARTICULARS

6.1

List of excipients

6.2

Name

Specification

Reference

%w/v

Water for Injections in bulk

EP

TO

100

Hydrochloric Acid

EP

QS

Sodium Hydroxide

BP

QS

Incompatibilities
Incompatible with amiodarone, amphotericin B, amsacrine and sodium nitroprusside.

6.3

Shelf life
500 ml polyethylene container - 36 months
500 ml polyolefin bag – 36 months.

6.4

Special precautions for storage
Store at 2° to 25°C

6.5

Nature and contents of container
Sealed semi-rigid, cylindrical neutral polythene container with a ‘Twist-off’ seal at
one end and a ring tab at the opposite end

Or
A flexible 500 ml polyolefine bag sealed in a polyolefine overwrap.

6.6

Special precautions for disposal
Polyfusor:
Do not dilute before use.
Use standard sterile peritoneal dialysis equipment.
freeflex
Opening the overwrap
Locate the corner tabs at the end of the bag. Grip the two tabs and pull the two halves
of the overwrap apart, releasing the bag onto a clean surface.
Setting up the solution
Position the roller clamp of the giving set to just below the drip chamber and close.
Hold the base of the giving set port firmly and grip the wings of the twist off tab.
Twist to remove the protective cover.
Still holding the base of the giving –set port push the set spike, fully into the port to
ensure a leak proof connection.

7

MARKETING AUTHORISATION HOLDER
Fresenius Kabi Limited
Cestrian Court
Eastgate Way
Manor Park
Runcorn
Cheshire
WA7 1NT

8

MARKETING AUTHORISATION NUMBER(S)
PL 08828/0051

9

DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
20/04/1989 / 15/08/2001

10

DATE OF REVISION OF THE TEXT
22/02/2010

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide